Type 2 diabetes (combination) represent 58.0% of application demand and direct accounts for 64.0% of sales channel sales in 2026. The linagliptin market is estimated at USD 8.1 million in 2026, is projected to reach USD 18.1 million by 2036 and is forecast to post an 8.4% CAGR between 2026 and 2036.